Literature DB >> 19889263

Remission of Grave's disease after oral anti-thyroid drug treatment.

Osama Ishtiaq1, Sabiha Waseem, M Naeemul Haque, Najmul Islam, Abdul Jabbar.   

Abstract

OBJECTIVE: To evaluate remission rate of anti-thyroid drug treatment in patients with Grave's disease, and to study the factors associated with remission. STUDY
DESIGN: A cross sectional study. PLACE AND DURATION OF STUDY: The Endocrine Department of the Aga Khan University Hospital, Karachi from 1999 to 2000.
METHODOLOGY: Seventy four patients of Grave's disease were recruited who were prescribed medical treatment. Grave's disease was diagnosed in the presence of clinical and biochemical hyperthyroidism along with anti-microsomal (AMA) and anti-thyroglobulin antibodies (ATA) and thyroid scan. These patients were prescribed oral anti-thyroid drugs using titration regime and followed at 3, 6, 12 and 18 months. Patients were categorized into two groups: "remission group" and "treatment failure group" and results were compared using a chi-square test, t-test and logistic regression model with significance at p < 0.05.
RESULTS: A majority of the patients were females (62.6%, n=46). During the follow-up period of 18 months, 41.9% patients went into remission. Univariate analysis showed that the initial free T4 level was significantly different (p < 0.05) in patients in remission and treatment failure groups. Multivariate analysis showed only initial free T4 level was a significant predictor of outcome. Positive AMA patients (n=27) had higher treatment failure (odds ratio: 2.55: 95%, CI 0.69 - 9:31), although the difference was not statistically significant (p = 0.13).
CONCLUSION: Remission rates with oral anti-thyroid agents is markedly high. Patients should be offered alternate treatment options to those who do not enter remission during a period of 12-18 months of treatment, those who develop relapse, and those who have aggressive disease on initial presentation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889263     DOI: 11.2009/JCPSP.690693

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  4 in total

1.  Clinical efficacy of Yingliu treatment for Graves disease.

Authors:  Hua Yang; Xiaojuan Bi; Hong Tang; Juanhua Zeng; Yilei Cong; Tengfei Wu; Qiuye Chen
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Predictors of long-term remission in patients with Graves' disease: a single center experience.

Authors:  Panagiotis Anagnostis; Fotini Adamidou; Stergios A Polyzos; Simoni Katergari; Eleni Karathanasi; Chrisanthi Zouli; Athanasios Panagiotou; Marina Kita
Journal:  Endocrine       Date:  2013-02-11       Impact factor: 3.633

3.  Technetium uptake predicts remission and relapse in Grave's disease patients on antithyroid drugs for at least 1 year in South Indian subjects.

Authors:  Neha Singhal; V P Praveen; Nisha Bhavani; Arun S Menon; Usha Menon; Nithya Abraham; Harish Kumar; R V JayKumar; Vasantha Nair; Shanmugha Sundaram; Padma Sundaram
Journal:  Indian J Endocrinol Metab       Date:  2016 Mar-Apr

4.  Comparison Between the Treatment Modalities for Graves' Disease at King Abdulaziz Medical City, Jeddah.

Authors:  Hawazen A Zarif; Sultan S Alam; Abdulrahman Baashar; Abdulaziz Alsharif; Mashael Alhilabi
Journal:  Cureus       Date:  2020-01-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.